Some papers to read today suggested by Wafik S. El-Deiry
Wafik S. El-Deiry, Associate Dean for Oncologic Sciences at the Warren Alpert Medical School, shared the following studies on X:
1. Spatially Segregated Macrophage Populations Predict Distinct Outcomes in Colon Cancer
by Magdalena Matusiak, John W. Hickey, David G.P. van IJzendoorn, Guolan Lu, Lukasz Kidziński, Shirley Zhu, Deana R.C. Colburg, Bogdan Luca, Darci J. Phillips, Sky W. Brubaker, Gregory W. Charville, Jeanne Shen, Kyle M. Loh, Derick K. Okwan-Duodu, Garry P. Nolan, Aaron M. Newman, Robert B. West, Matt van de Rijn.
2. Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors
by Gabriel Espinosa-Carrasco, Edison Chiu, Aurora Scrivo, Paul Zumbo, Asim Dave, Doron Betel, Sung Wook Kang, Hee-Jin Jang, Matthew D. Hellmann, Bryan M. Burt, Hyun-Sung Lee, Andrea Schietinger.
3. Is mitochondrial morphology important for cellular physiology?
by Timothy Wai.
4. Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study
by Bob T Li, MD, Prof Funda Meric-Bernstam, MD, Aditya Bardia, MD, Yoichi Naito, MD, Prof Salvatore Siena, MD, Philippe Aftimos, MD, Ian Anderson, MD, Prof Giuseppe Curigliano, MD, Maria de Miguel, MD, Maitri Kalra, MD, Prof Do-Youn Oh, MD, Prof Joon Oh Park, MD, Sophie Postel-Vinay, MD, Prof Sun Young Rha, MD, Prof Taroh Satoh, MD, Iben Spanggaard, MD, Flavia Michelini, PhD, Ann Smith, MSc, Karime Kalil Machado, MD, Cristina Saura, MD.
5. Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial
by Herui Yao, MD, Min Yan, MD, Zhongsheng Tong, MD, Xinhong Wu, MD, Min-Hee Ryu, PhD, John J. Park, PhD, Jee Hyun Kim, PhD,Yahua Zhong, MD, Yiming Zhao, MD, Mark Voskoboynik, MB, Yongmei Yin, MD, Kan Liu, MB, Andreas Kaubisch, MD, Caigang Liu, PhD, JianZhang, MD, Shouman Wang, PhD, Seock-Ah Im, PhD, Vinod Ganju, MB, Minal Barve, MD, Hui Li, MB, Changsheng Ye, MD, Amitesh C. Roy, MD, Li-Yuan Bai, MD, Chia-Jui Yen, MD, Shanzhi Gu, MD, Yung-Chang Lin, MD, Lingying Wu, MD, Lequn Bao, MM, Kaijing Zhao, PhD, Yu Shen, PhD, Shangyi Rong, PhD, Xiaoyu Zhu, PhD, and Erwei Song, MD.
6. Experiences of Leaders in Diversity, Equity, and Inclusion in US Academic Health Centers
by Caitlin J. Esparza, MD; Mark Simon, MA; Maya R. London, BA; Eraka Bath, MD; Michelle Ko, MD, PhD.
”
Source: Wafik S. El-Deiry/X
Wafik El-Deiry, MD, PhD, FACP, FRSM, is the Associate Dean for Oncologic Sciences at the Warren Alpert Medical School and Director of the Legorreta Cancer Center at Brown University and Director of the Joint Program in Cancer Biology at Brown University and affiliated hospitals.
Dr. El-Deiry discovered p21(WAF1) as a p53 target gene, cell cycle inhibitor, and tumor suppressor that explained the mammalian cell stress response. Dr. El-Deiry’s research is focused on mechanisms of therapy resistance with major efforts in drug discovery and development.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023